ACTIVE SPECIFIC IMMUNOTHERAPY WITH TUMOR-CELLS AND CORYNEBACTERIUM-PARVUM - PHASE-I STUDY

被引:0
作者
MCCUNE, CS
PATTERSON, WB
HENSHAW, EC
机构
[1] UNIV ROCHESTER, SCH MED & DENT, DEPT MED, ROCHESTER, NY 14627 USA
[2] UNIV ROCHESTER, CTR CANC, ROCHESTER, NY 14627 USA
[3] UNIV ROCHESTER, SCH MED & DENT, DEPT SURG, ROCHESTER, NY 14627 USA
关键词
D O I
10.1002/1097-0142(197905)43:5<1619::AID-CNCR2820430509>3.0.CO;2-O
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Autologous, irradiated (10,000 rads) tumor cells mixed with C. parvum [Propionibacterium acnes] were given as weekly intracutaneous injections to 15 patients with residual malignant disease. The toxicity was minimal and distinctly less than has been seen with tumor cell-BCG immunotherapy. A goal of 4 injections of 107 cells each was possible in only 4 patients because of limitations in methods of disaggregation and quantity of tumor available. The feasibility aspects are discussed and a case report of a prolonged regression is presented.
引用
收藏
页码:1619 / 1623
页数:5
相关论文
共 17 条
[1]  
BARTLETT GL, 1972, J NATL CANCER I, V48, P1709
[2]   ACTIVE SPECIFIC IMMUNOTHERAPY OF MOUSE METHYLCHOLANTHRENE INDUCED TUMORS WITH CORYNEBACTERIUM-PARVUM AND IRRADIATED TUMOR-CELLS [J].
BOMFORD, R .
BRITISH JOURNAL OF CANCER, 1975, 32 (05) :551-557
[3]  
CATALONA W J, 1972, New England Journal of Medicine, V286, P399, DOI 10.1056/NEJM197202242860804
[4]   ACTIVE IMMUNOTHERAPY AS AN ADJUNCT TO CHEMOTHERAPY IN TREATMENT OF DISSEMINATED MALIGNANT-MELANOMA - PILOT-STUDY [J].
CURRIE, GA ;
MCELWAIN, TJ .
BRITISH JOURNAL OF CANCER, 1975, 31 (02) :143-156
[5]  
GERCOVICH F G, 1975, Medical and Pediatric Oncology, V1, P277, DOI 10.1002/mpo.2950010310
[6]  
GERNER RE, 1976, CANCER-AM CANCER SOC, V38, P131, DOI 10.1002/1097-0142(197607)38:1<131::AID-CNCR2820380122>3.0.CO
[7]  
2-K
[8]   IMMUNOPOTENTIATION WITH BCG - DIMENSIONS OF A SPECIFIC ANTITUMOR RESPONSE [J].
HAWRYLKO, E .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1975, 54 (05) :1189-1197
[9]  
HUDSON CN, 1976, LANCET, V2, P877
[10]  
LAUCIUS JF, 1977, CANCER-AM CANCER SOC, V40, P2091